Evidence map›Paper›PMID 42439217›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Design of a Wobble-Scheme Heterojunction for Catalytic Cancer Therapy.

Xinmiao Hou, Jing Zhang, Xixi Zhao, Yunxiang Zhang, Siyu Zhao, Zhaoxin Sun, Derui Xu, Qing Song, Ruijie Zhao, Peter R Taylor and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xinmiao HouSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Jing ZhangSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Xixi ZhaoTianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin, China.
Yunxiang ZhangSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Siyu ZhaoSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Zhaoxin SunSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Derui XuTianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin, China.
Qing SongSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Ruijie ZhaoSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
Peter R TaylorSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.ORCID 0000-0002-3110-5361
Xichuan LiTianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin, China.
Xinghua JinSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.ORCID 0000-0002-8883-5234

Funding

National Natural Science Foundation of China 81872236
6 · The paper itself

Abstract

Nanocatalytic medicine has emerged as a promising strategy for tumor therapy, where the rational design of photocatalytic nanoscale heterostructures plays a pivotal role. Herein, an organic-inorganic core-shell nanoreactor (Bi@COF) is designed as a wobble-scheme heterojunction with responsiveness to the tumor microenvironment (TME). In the acidic TME, the COF shell undergoes reversible enolimine-ketoenamine tautomerization, enabling dynamic switching between reduction/oxidation (RP/OP) junctions. Under near-infrared irradiation (NIR), the reconfigured heterojunction efficiently catalyzes in situ H

Indexed as

NeoplasmsCatalysisHumansHydrogen PeroxidePhotochemotherapyReactive Oxygen SpeciesTumor MicroenvironmentHydrogen PeroxideReactive Oxygen Speciesheterojunctionphotocatalysisproton‐coupled electron transfertautomerization

Identifiers

PMID42439217
PMCPMC13533273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.